Conbercept, a new drug of Kanghong pharmaceutical industry, makes the world amazing

Chinese ophthalmologists reported in the United States Monday that their clinical trials showed that conbercept, a new drug independently developed by Chengdu Kanghong Pharmaceutical Co., could significantly improve the vision of patients with wet age-related macular degeneration (w-amd) Age-related macular degeneration refers to the aging change of macula in the center of retina The disease can cause vision loss or decline, which is the main cause of vision damage in the elderly There are two types of macular degeneration in the elderly: dry and wet The main cause of blindness is wet macular degeneration The incidence rate of Chinese wet macular degeneration is 4 times that of Westerners, and the incidence rate of people over 60 is over 10%, according to the study This is a kind of eye fundus disease which is very harmful and easy to be ignored It is one of the main causes of blindness, and it is also recognized as a persistent disease in the global eye field In the past, the drugs used to treat macular degeneration of the fundus in China were imported, expensive and needed to be injected every month, which made many patients look forward to the drugs Patients are eager for more effective and cost-effective drugs! Two experts from China became the focus of the 12th Annual Conference on neovascularization held in Miami, USA Professor Li Xiaoxin of Peking University People's Hospital and Professor Ding Xiaoyan of Sun Yat sen University Eye Center announced the two latest clinical research results of conbercept ophthalmic injection (trade name "Langmu") respectively at the conference, which aroused the warm response of experts attending the conference "Retina today", a famous international ophthalmic media, interviewed two professors for the first time As a leader in ophthalmology in China, Professor Li Xiaoxin expressed his fervent hope for conbercept: "we are very glad to have the opportunity to continuously push China's original research products to the world stage in a professional way, in fact, to show China's strength and future!" Professor Ding Xiaoyan showed in the special report of the International Conference on the same day that 30 elderly patients with advanced wet macular degeneration participated in the three-year study The average age of these people was 69 years old, and their best corrected vision was less than 0.05, almost blind In the first three months of the trial, the patients received intraocular injection of conbercept once a month, and in the next three months, the patients were treated as needed according to the specific conditions of each patient The study used a special vision chart called "ETDRS", which sets the "all blind" level as one letter, and the vision level of 2.0 as 100 letters After 6 months, the best corrected visual acuity of about 85% of the subjects was improved to more than 19 letters, that is to say, to see the light again The average visual acuity level of all patients increased by 24 letters on the original basis, of which 73% of the subjects' visual acuity improved by more than 15 letters, and the quality of life of the patients was significantly improved Various imaging examinations also confirmed that the macular lesions of the subjects were well controlled and recovered Ding said the results were "very encouraging" and confirmed that conbercept was equally effective in patients with very low vision who were in the late stages of the disease In addition, no drug-related adverse reactions were found during the test, which indicated the safety of conbercept Conbercept is an independent R & D and independent intellectual property "created in China" by Chengdu Kanghong Pharmaceutical Group It is a representative achievement of the national 11th five year plan major new drug creation project, and also the first biological new drug in China to obtain the international common name As one of the representative achievements of the national implementation of the major strategic decision of "innovation driven development", it was evaluated by professional news media as the most valuable product among the new drugs approved by the State Food and Drug Administration in 2013 On December 4, 2013, CCTV channel 1 and news channel broadcast the listing news of conbercept three times in one day Later, a special film crew was sent to report the global kick-off meeting of conbercept at the last annual meeting of new blood vessels in the United States This is the only thing in the history of Chinese medicine! Conbercept is a new generation of 100% human-derived recombinant fusion protein Compared with the imported monoclonal antibodies that only act on one target of VEGF-A in the market, Lanmu also acts on the targets of VEGF-A, VEGF-B and PlGF (placental growth factor) In the treatment of wet AMD, once a month in the initial three months, the vision of the patients was significantly improved After that, once every three months or as needed, the patients could maintain the best efficacy and significantly reduce the frequency of medication This not only reduces the sufferings and treatment risks of patients, but also greatly reduces the economic burden of patients' families and society It's no accident that conbercept came out of the world It has been supported by experts and governments at all levels It's also inseparable from the innovative spirit and unremitting efforts of Kanghong pharmaceutical industry When the first conbercept ophthalmology Summit Forum (caaos) was held, Professor Wang Ningli, chairman of the ophthalmology branch of the Chinese Medical Association, who was originally going to Taipei to participate in the Asian keratology Association (ACS), specially adjusted it "It's not easy for Chinese people to have an aspiring medicine and a first-class medicine to enter the world," he said after arriving at the scene as the president of the conference Professor Yao Ke, chairman designate of Ophthalmology branch of Chinese Medical Association, once said: "as a member of the Standing Committee of CPPCC National Committee, as a national chairman designate of Ophthalmology, I stand a clear stand to support the development and expansion of national brands!" In addition, the second phase of Kanghong biological technology upgrading project has received tens of millions of special funds support from the national development and Reform Commission and the Ministry of finance through the government and experts' selection at various levels There are less than 10 biomedical enterprises that have received such support nationwide, which highlights the confidence, trust and support of the state for Kanghong! The successful listing of conbercept has attracted great attention from the global eye industry At the international eye Festival, conbercept has become the speech theme of top experts at home and abroad; multinational pharmaceutical giants actively contact conhong to discuss international cooperation issues; According to the normal market logic, the price of such a new generation of products is often higher than that of the previous generation However, conbercept's annual treatment cost is less than 40% of the previous generation of imported products! This may not be in line with the pursuit of commercial profits, but Kanghong people bear in mind the original intention - "Kangping Shengshi, Hongji all living beings; Innovation, in order to better serve the patients "! Let more elderly patients with macular degeneration use conbercept and see the bright world again! Therefore, although conbercept's R & D took ten years and invested hundreds of millions, conhong not only adopted the policy of small profits and high sales, but also built the" bright vision, Mu Guang "public welfare assistance together with the 4A level public welfare organization of the Ministry of civil affairs, China Social Assistance Foundation The project aims to help the economically poor patients and reduce the medical burden of the society and families through free drug donation and other ways In addition, through various forms of public welfare publicity, free diagnosis and other ways, the elderly will be screened for diseases and disease knowledge education, so that patients can understand and pay attention to AMD, and understand that as long as early detection and treatment are carried out, effective vision can be maintained Conbercept has won the favor of ophthalmologists and patients all over the country by virtue of its excellent curative effect and good economy compared with imported products It has created a few sales achievements in the history of Chinese medicine within less than one year since its launch Kanghong people are not satisfied with the achievements they have made They have looked to the international market "From design, R & D, production to marketing, Kanghong has a global perspective, providing a cost-effective brand product for the world, and turning the products originally researched in China into world brands." Yin Jinqun, vice president of Kanghong Pharmaceutical Group, said frankly that the road of internationalization is very difficult Not only are there too many foreign policy barriers, but also the inherent prejudice against China Sometimes they have to bear the arrogance of western countries "Even so, we will move forward unswervingly, and someone will always be the leader." In fact, Kanghong's challenge is that of all Chinese enterprises who want to go abroad Huawei, Lenovo and China's high-speed rail have all experienced similar hardships in the process of internationalization However, enterprises like Kanghong are always trying to open up a path: successful innovation - industrialization - training talents - assisting the state in formulating standards - national brand internationalization Only in this way can more patients benefit from innovative R & D products, and only in this way can Chinese pharmaceutical brands step onto the international stage in the fierce market competition, and promote the transformation of China from a pharmaceutical power to a pharmaceutical power!